Zymeworks (ZYME) investor relations material

Executive summary

• Achieved key regulatory milestones for zanidatamab, including FDA Priority Review with PDUFA date set for August 25, 2026, and sBLA filings accepted in both the U.S. and China, positioning for significant milestone payments and long-term royalties.

• Entered into a $250 million royalty-backed loan with Royalty Pharma, monetizing 30% of future zanidatamab royalties to support share repurchases and strategic acquisitions.

• Advanced ADC pipeline with promising preclinical and clinical data, notably for pan-RAS ADCs and ZW191, supporting R&D scalability and innovation.

• Strengthened leadership team with key executive appointments to enhance capital allocation, execution, and strategic transactions.

• Presented practice-changing Phase 3 data for zanidatamab in 1L HER2+ GEA and highlighted innovation in ADCs and multispecifics at major conferences.

Financial highlights

• Q1 2026 revenue was $2.4 million, down sharply from Q1 2025 due to non-recurring milestone payments; ongoing collaboration and royalty revenue expected to grow.

• R&D expenses were $34.5 million, reflecting a shift in program mix and reduced spending on later-stage and discontinued programs.

• G&A expenses decreased to $15.1 million, mainly due to lower professional fees and consulting costs.

• Net loss widened to $44.2 million from $22.6 million year-over-year, primarily due to lower revenue.

• Cash, cash equivalents, and marketable securities totaled $403.8 million as of March 31, 2026, up from $270.6 million at year-end 2025, bolstered by royalty monetization and stock option exercises.

Outlook and guidance

• Anticipates $440 million in regulatory milestone payments upon potential approvals in major markets, with $250 million from the U.S. and $15 million from China, expected to fund operations beyond 2028.

• Expects continued growth in royalty revenue as commercial sales of Ziihera increase.

• Guidance for approximately $300 million in aggregate adjusted gross operating expenditures (non-GAAP) over three years ending December 31, 2028, with higher expenses in 2026 and declines in 2027 and 2028.

• IND for ZW1528 now guided for 2027, with additional IND and regulatory submissions planned for other pipeline assets.